The Bactericidal Activity of Moxifloxacin in Patients with Pulmonary Tuberculosis-Reference-Cited by-同舟云学术

The Bactericidal Activity of Moxifloxacin in Patients with Pulmonary Tuberculosis

Published:2003-12 Issue:11 Volume:168 Page:1342-1345
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Gosling Roly D.,Uiso Leonard O.,Sam Noel E.,Bongard Emily,Kanduma Esther G.,Nyindo Mramba,Morris Richard W.,Gillespie Stephen H.

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference26 articles.

1. Pablos-Mendez A. Working alliance for TB drug development, Cape Town, South Africa, February 8th, 2000.Int J Tuberc Lung Dis2000;4:489–490.

2. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications.Int J Tuberc Lung Dis1999;3:S231–S279.

3. Whither short-course chemotherapy?

4. Global Trends in Resistance to Antituberculosis Drugs

5. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis?Int J Tuberc Lung Dis1998;2:265–271.

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Update to Novel Therapeutic Options for Combating Tuberculosis: Challenges and Future Prospectives;Current Pharmaceutical Biotechnology;2024-10

2. Testing novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB): protocol for a randomised controlled trial;Trials;2024-05-08

3. Evaluation of critical parameters in the hollow‐fibre system for tuberculosis: A case study of moxifloxacin;British Journal of Clinical Pharmacology;2024-04-17

4. Testing Novel Strategies for Patients Hospitalized with HIV-associated Disseminated Tuberculosis (NewStrat-TB): Protocol for a Randomised Controlled Trial;2024-04-01

5. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs;European Respiratory Journal;2023-06-15